Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

Sameh Gaballa, MD, Neil D. Palmisiano, MD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Ubaldo Martinez, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD, Dolores Grosso, DNP

Blood (2014) 124 (21): 1212.

https://doi.org/10.1182/blood.V124.21.1212.1212

Published: 2014

Journal Articles

CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

Mahasweta Gooptu, MD, Benjamin Leiby, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez, MD, Barbara Pro, MD, Manish Sharma, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD, Dolores Grosso, DNP

Blood (2014) 124 (21): 1170.

https://doi.org/10.1182/blood.V124.21.1170.1170

Published: 2014

Journal Articles

A 2 Step Approach To Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Low Non-Relapse Related Mortality (NRM) and High Overall Survival (OS) Rates Confirmed In Second Generation Trial

Dolores Grosso, DNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Ubaldo Martinez, MD, William O'Hara, PharmD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD

Blood (2013) 122 (21): 3360.

https://doi.org/10.1182/blood.V122.21.3360.3360

Published: 2013

Journal Articles

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

Neil D. Palmisiano, MD, Sameh Gaballa, MD, Bijoyesh Mookerjee, MD, John L. Wagner, MD, Margaret Kasner, MD, Matthew Carabasi, MD, Onder Alpdogan, MD, Ubaldo Martinez, MD, Mark Weiss, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2013) 122 (21): 2689.

https://doi.org/10.1182/blood.V122.21.2689.2689

Published: 2013

Journal Articles

Stroke in Sickle Cell Anemia After Excellent Response to Hydroxyurea.

Ubaldo Martinez, MD, Samir K. Ballas, MD

Blood (2009) 114 (22): 4622.

https://doi.org/10.1182/blood.V114.22.4622.4622

Published: 2009

NARROW

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

A 2 Step Approach To Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Low Non-Relapse Related Mortality (NRM) and High Overall Survival (OS) Rates Confirmed In Second Generation Trial

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

Stroke in Sickle Cell Anemia After Excellent Response to Hydroxyurea.

Email alerts

ASH Publications

American Society of Hematology

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

A 2 Step Approach To Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Low Non-Relapse Related Mortality (NRM) and High Overall Survival (OS) Rates Confirmed In Second Generation Trial

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

Stroke in Sickle Cell Anemia After Excellent Response to Hydroxyurea.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only